Introduction
Two biologically active forms of somatostatin have been identified, SS-14 and SS-28. These peptides exert a wide variety of actions, which include inhibition of secretory and proliferative processes in many target organs. 1 The effects of somatostatin are mediated via high affinity, seven-transmembrane G-protein-coupled receptors (ssts). 2, 3 Human ssts are encoded by a family of five genes, localized on different chromosomes. 3 Each sst subtype displays a marked degree of structural conservation across species. Ssts are widely distributed among many tissues and some cell types express multiple sst subtypes. [3] [4] [5] The five receptors share common signaling pathways, involving the inhibition of adenylyl cyclase, activation of phosphotyrosine phosphatase (PTP), and modulation of mitogen-activated protein kinase (MAPK). [3] [4] [5] Several biological responses to somatostatin have been identified that display absolute or relative receptor subtype selectivity. These include growth hormone secretion (induced via sst 2 and sst 5 ), insulin secretion (sst 5 ), glucagon secretion (sst 2 ), and immune responses (sst 2 ). 6 Previously, ssts have been detected in human lymphoid tissues, lymphoid cell lines and peripheral blood cells. [7] [8] [9] [10] [11] [12] [13] [14] RT-PCR-based sst subtype analysis indicated that human peripheral blood B and T lymphocytes express only sst 3 , while monocytes, upon activation with LPS, express sst 2 (LichtenauerKaligis, submitted). Ssts are also present on cells derived from several hematological malignancies, including malignant lym- phomas, 7, 15 acute myeloid leukemias and lymphoblastic leukemias. 16, 17 However, which receptor subtype(s) are expressed on these malignant cells has not been investigated.
We have recently shown that, of the 5 sst subtypes, only sst 2 is expressed on a primitive subset of normal bone marrow cells (CD34 + /CD117 + ) (Oomen, submitted for publication). Interestingly, sst 2 expression is lost when cells acquire immunophenotypic markers of differentiation towards the lymphoid, myeloid and/or erythroid lineages. We also found that somatostatin and octreotide, a stable analogue of somatostatin, act as chemoattractants for human primitive hematopoietic (CD34 + ) cells, including the clonogenic progenitors CFU-GM and BFU-E. This somatostatin-mediated mechanism may be of importance in vivo, in the homing of BM progenitors/stem cells to different organs or to different niches within these organs, during development and/or adult life.
In this study, we analyzed the expression pattern of sst subtypes on acute myeloid leukemia (AML) cells and investigated whether somatostatin influences migration of AML cells. Our results show that, like normal human bone marrow (hBM) cells, AML blasts exclusively express sst 2 . However, in contrast to normal hBM, sst 2 expression in AML is not always restricted to the CD34 + cells. AML cells showed variable migration properties towards an octreotide gradient, which correlated with the expression levels of sst 2 on the AML cells. These findings indicate that SS-mediated mechanisms may influence the migratory behavior of AML blasts, which might have consequences for compartmentalization and spreading of the leukemic cells in vivo.
Materials and methods

Isolation of AML cells
Bone marrow cells were obtained from 16 patients with AML (five M1, two M2, three M4 and six M5) following informed consent. The marrow cells were collected in Hank's balanced salt solution (HBSS) supplemented with heparin. Mononuclear, T lymphocyte-depleted and monocyte-depleted (only M1 and M2 AML samples) cells were collected and cryopreserved prior to use as described previously. 18, 19 The AML samples used contained at least 95% blasts.
Reverse transcriptase polymerase chain reaction (RT-PCR)
To determine sst subtype and somatostatin expression, RT-PCR was performed as described. 20 In brief, polyA + mRNA was isolated from 10 6 cells per sample using Dynabeads Oligo (dT) 25 (Dynal, Oslo, Norway). cDNA was synthesized using the polyA + mRNA captured on the Dynabeads Oligo (dT) 25 . One-tenth of each cDNA sample immobilized on the para- 29 for hsst 5 from Kubota et al. 30 All other primers were designed by use of the Primer3! software (http://www-genome.wi.mit.edu/genomeFsoftware/other/primer3.html) and the appropriate GenBank entries. b The position is given of the 5Ј nucleotide of the primer relative to the first nucleotide of the coding region in the cDNA sequence. c The sst 2 primers are specific for sst 2A . FW, forward primer; RV, reverse primer.
magnetic beads was used per amplification. Oligonucleotide primers specific for the human somatostatin receptor subtypes sst [1] [2] [3] [4] [5] (sst 2 primers are specific for sst 2A ), somatostatin and hypoxanthine-guanine phosphoribosyl transferase (HPRT) are described in Table 1 . PCR was carried out in a DNA thermal cycler with heated lid (Perkin Elmer, Nieuwerkerk a/d IJssel, The Netherlands). After an initial denaturation at 95°C for 5 min, samples were subjected to 33 (sst 2 ) or 40 (all others) cycles of denaturation at 94°C for 1 min, annealing for 2 min at 59°C and extension for 1 min at 72°C. PCR products were analyzed by electrophoresis on 1.5-2% agarose gels stained with ethidium bromide.
Flow cytometric analysis of somatostatin binding to AML blasts
To determine somatostatin binding to AML blasts, cells were incubated with 50 nM of Fluo-somatostatin (Advanced Bioconcept, Montreal, Quebec, Canada) for 45 min at RT in the dark. Fluo-SS binds to sst subtypes 1, 2 and 3 but not to sst 4 and sst 5 (according to the manufacturer). Non-specific binding was assessed in parallel incubations, in which a 100-fold excess of (D-Trp 8 )-somatostatin-14 (BACHEM, Bubendorf, Switzerland) was added. Human AML cells were double stained with R-phycoerythrin (PE)-conjugated antibodies against human CD34 or CD117 (CD34-PE, CD117-PE,1:10 vol/vol; Beckman Coulter, Mydrecht, The Netherlands) or IgG 1 -PE (1:10 vol/vol, Becton Dickinson) for 30 min at 4°C. Stained cells were suspended in phosphate-buffered saline (PBS), supplemented with 0.05% NaN 3 and 1% fetal calf serum (FCS). Cells were then subjected to flow cytometric analysis on a FACScan (Becton Dickinson, Sunnyvale, CA, USA). A gate was set on the basis of forward sideward light scatter to exclude dead cells from the analysis.
Immunochemical detection of sst 2
AML cytospins were stained with sst 2A (R2-88) antibody as described earlier. 21 A standard streptavidin-biotinylated-peroxidase complex (ABC) kit (Biogenix, San Ramon, CA, USA) was used to visualize the bound antibodies. Stainings with R2-88 antibody pre-adsorbed with the immunizing receptor peptides (at a concentration of 0.3 g/ml = 100 nM) were performed as negative controls.
Cell migration assays
Transwell migration assays were performed with 5 m pore filters (Transwell, 6.5 mm diameter, 24-well cell clusters; Costar, Cambridge, MA, USA), pre-coated overnight at 4°C with 20 g/ml fibronectin (bovine plasma: 0.1% in 0.5 M NaCl/0.05 M Tris pH 7.5, Sigma F 1141) as previously described. 22 In brief, 2 × 10 5 cells in 100 l migration buffer (Iscove's medium, 0.5% BSA) were added to the upper chamber and 0.6 ml of migration buffer was added to the lower chamber. Increasing concentrations of octreotide were added to the migration buffer in the lower chamber to determine the optimal concentrations required for migration. In some experiments, octreotide (10 −10 M) was placed in the upper and/or lower chamber. Chambers were incubated at 37°C, 5% CO 2 for 4 h. Cells migrating towards the lower chamber were counted using a cell counter (CASY 1/TTC, Schärfe Systems, Reutlingen, Germany).
Statistical analysis
Standard linear regression analysis (sst 2 mean fluorescence vs migration) was determined using a two-tailed Spearman's rho test. The correlation is considered significant at the 0.01 level (two-tailed). 
Results
Sst expression on human AML cells
Somatostatin receptors have been described to be present on human AML cells. 16 To determine which sst subtypes are Leukemia expressed on these cells, we isolated mRNA from AML cells and performed RT-PCR analysis using primers specific for the different sst subtypes. Similar to normal human bone marrow, only sst 2 transcripts were detected ( Figure 1 ). We also investigated whether AML blasts produce somatostatin. In the 16 AML samples analyzed by RT-PCR, somatostatin transcripts FAB, French-American-British AML classification; MF, mean fluorescence after subtracting the MF of control samples (fluorescent signal with excess of unlabeled somatostatin); + expression of CD34 or CD117 on the AML blasts; − no expression of CD34 or CD117 on the AML blasts; spontaneous migration, control medium in the lower chamber; induced migration, octreotide-containing medium in the lower chamber; migration fold induction, data are expressed as fold induction of migration as compared to when no octreotide was added to the lower chamber (=1); optimal oct concentration, octreotide concentration (M) at which maximum cell migration occurred. could not be detected (Figure 1 ), ruling out autocrine and/or paracrine effects on sst 2 -mediated migration. Sst 2 mRNA was found in all AML samples, indicating that at least basal levels of sst 2 were produced. Flow cytometric analysis with Fluo-SS showed that AML cells express variable amounts of sst 2 on the cell membrane (Figure 2 ). Of the 16 cases of AMLs tested, 13 showed specific Fluo-SS binding, with a mean fluorescence intensity ranging from 1.2 to 17 ( Table 2 ). In this cohort of AMLs no relationship was evident between morphological classification (French-American-British group) and the levels of Fluo-SS binding. As expected, Fluo-SS binding of AML cells could be completely blocked not only by D-Trp 8 -SS, but also by octreotide, confirming that the binding capacities of these ligands for sst 2 are similar (data not shown). The expression of sst subtype 2 was confirmed by immunochemistry using an antibody (R2-88) specific for sst 2 (Figure 3) .
Distribution of sst among immunophenotypic subsets of AML
We have recently shown that sst 2 expression in normal hBM is confined to CD34 + and CD117 + (c-kit + ) expressing cells (Oomen, submitted for publication). Strikingly, this restricted expression of sst 2 was not seen in AML. In some cases, both CD34 +
/CD117
+ and CD34 − /CD117 − were found to express high levels of sst 2 (Figure 4a ), while in others CD117
+ AML cells showed a higher sst 2 expression than CD117 − cells (Figure 4b) . Notably, also in a case of CD34 − AML, high sst 2 levels were found (Figure 4c) . A summary of the Fluo-SS binding data is given in Table 2 . These findings establish that AML blasts show a markedly heterogeneous sst 2 expression, which frequently deviates from normal hBM progenitors. 
Leukemia
Octreotide induces migration of human AML bone marrow cells in vitro
We then assessed the migration properties of AML cells towards an octreotide gradient in a transwell assay. The response of AML blasts from different patients to an octreotide gradient was heterogeneous (Figure 5a ). Octreotide-induced migration was dose-dependent, with maximal migration at concentrations between 10 −11 M and 10 −10 M in most cases. Migration towards a negative gradient (Oct in the upper chamber) was negligible (Figure 5b) . However, in certain cases of AML, octreotide induced migration in absence of a chemoattractant gradient (Oct in the upper and lower chambers), which is indicative of chemokinesis, rather than chemotaxis (No. 14, Figure 5b ). Because AML cells from different patients showed variable spontaneous migration, we expressed the migration as fold induction of spontaneous migration (Table 2 ), which ranged from 1.1 (little or no induction) to 8.5. No relation was detected between spontaneous migration and sst expression. In contrast, octreotideinduced migration correlated with expression levels of sst 2 on the cell surface ( Figure 6 ).
Discussion
During different stages of fetal development and adult life primitive hematopoietic cells migrate between organs, eg fetal liver, bone marrow and spleen. In addition, stem cells can migrate towards the peripheral blood in response to several mobilizing agents. How the migratory behavior of hematopoietic stem cells and progenitor cells is governed is still largely unknown. Physiological stimuli of stem cell migration include various cytokines and chemokines. The major chemokine implicated in hematopoietic stem cell trafficking is stromal cell-derived factor-1 (SDF-1). 23 The receptor for SDF-1, CXCR4, is a 7-transmembrane G ␣i -coupled receptor that belongs to the family of chemokine receptors. A recent study showed that CXCR4 is also expressed on primary AML leukemic cells in variable amounts. 24 The expression level of CXCR4 determined the migratory response to SDF-1, indicating that the receptor was functionally active in these cells.
We have recently demonstrated that sst subtype 2 is expressed on a primitive subset of normal human bone marrow cells (CD34 + /CD117 + ) and that somatostatin induces migration of these cells in a transwell system (Oomen, submitted for publication). In the present study we analyzed the expression and function of sst 2 in primary human leukemia cells of 16 patients. Expression of sst 2 mRNA was detected in all AML samples, despite the fact that some of these samples were negative in Fluo-SS binding assays. Clearly, sst 2 expression on AML cells is heterogeneous and, unlike normal hematopoietic precursors, not limited to CD34 and CD117 expressing cells. It is conceivable that receptors do not function properly in malignant cells, even when expressed in large amounts on the cell surface. However, our results show that the level of sst 2 expression is directly related to the ability of the leukemic cells to migrate in response to the somatostatin analogue octreotide.
The presence of sst on a variety of human tumors suggests a role for somatostatin in the control of tumor development. Several tumors coexpress somatostatin along with ssts. The presence of sst in most of the neuroendocrine tumors together with the ability of many of those tumors to synthesize somatostatin point towards an autocrine regulatory feedback mech- Correlation of sst 2 expression and octreotide-induced migration of AML cells. A positive correlation (r = 0.799) was found between the expression level of sst 2 (MF = mean specific fluorescence of Fluo-somatostatin) and migration (fold induction) in response to octreotide. The correlation was significant (P Ͻ 0.001) as determined by a Spearman's rho test.
anism in these tissues. 25 However, we did not detect somatostatin transcripts in AML blasts by RT-PCR, which argues against such a mechanism in AML.
Somatostatin receives major attention in the treatment of hypersecretive neuroendocrine tumors, because of its inhibitory action on hormone production, as well as its direct suppression of neoplastic cell growth. 26 This has also stimulated an interest in the development of somatostatin analogues, which lack systemic side-effects, are relatively resistant to enzymatic degradation and thus show a longer half-life in vivo. 27 Somatostatin may act as a negative regulator of the proliferative activity of human myeloid leukemia 16 and preliminary data demonstrated a partial remission in 36% of patients with low-grade non-Hodgkin's lymphomas treated with octreotide. 28 The accurate evaluation of sst subtype status in hematological diseases may become of value in the treatment of these patients when new subtype selective analogues are available for clinical applications such as radiotherapy with radionuclide-coupled somatostatin analogues or chemotherapy with 'toxin' coupled somatostatin analogues. Our finding that somatostatin and octreotide influence the migratory behavior of AML blasts, suggests that treatment with these peptides may also have consequences for compartmentalization and spreading of the leukemic cells in vivo. A future goal is to explore this in a relevant model, eg in NOD/SCID mice xenografted with human AML cells.
